29 Results for "

renal impairment

" in MedChemExpress (MCE) Product Catalog:
Products (29)

29 Results for "renal impairment" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-101126
CAS No.: 1361951-15-6
Purity:  99.96%
Synonyms: TP-3654
Research Areas:  

Cancer

Nuvisertib (TP-3654) is an orally active second-generation pan-PIM kinase inhibitor with Ki values of 5 nM, 239 nM, and 42 nM against PIM-1, PIM-2, and PIM-3, respectively. Nuvisertib inhibits JAK-independent inflammatory and survival signaling pathways, reduces the production of proinflammatory cytokines, restores apoptotic sensitivity, inhibits mTORC1, MYC, and TGF-β signaling pathways, and decreases the expression of fibrosis markers. Nuvisertib selectively impairs the transport function of ABCG2, resensitizes multidrug-resistant cancer cells to cytotoxic drugs, and overcomes JAK2 inhibitor resistance. Nuvisertib can be used in research related to myelofibrosis, renal cell carcinoma, multidrug-resistant cancer, advanced solid tumors, urothelial carcinoma, and prostate adenocarcinoma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-117985B
CAS No.: 1222102-51-3
Purity:  99.71%
Synonyms: DA-1229 tartrate
Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-14744A
CAS No.: 150566-71-5
Purity:  99.84%
Synonyms: (S)-Amlodipine besylate; Levoamlodipine besylate
Target:  

Calcium Channel MMP

Research Areas:  

Cardiovascular Disease

Levamlodipine ((S)-Amlodipine; Levoamlodipin) besylate is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine besylate significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine besylate not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine besylate exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine besylate may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine besylate can be used in research related to hypertension and atherosclerosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-14744
CAS No.: 103129-82-4
Purity:  98.53%
Synonyms: (S)-Amlodipine; Levoamlodipine
Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W019894
CAS No.: 7773-01-5
Synonyms: Manganese dichloride
Manganese chloride is an orally active MRI liver contrast agent. Manganese chloride induces Apoptosis and activates the mTOR signaling pathway. Manganese chloride induces cognitive impairment, promotes hematopoietic recovery, and reduces radiation-induced bone marrow and brain damage. It can be used for the study of renal impairment .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W250122
CAS No.: 32221-81-1
Synonyms: Monosodium glutamate
Glutamic acid sodium salt (Monosodium glutamate) is an orally active food flavor enhancer. Glutamic acid sodium salt causes ROS generation, mitochondrial dysfunction, and Apoptosis. Glutamic acid sodium salt upregulates CHOP, Grp78, and Bcl-2. Glutamic acid sodium salt impairs cognition, induces depressive-like behavior, induces hyperalgesia, and induces obesity and insulin resistance. Glutamic acid sodium salt can be used to study neurotoxicity (e.g., brain damage, cognitive impairment), metabolic disorders (e.g., obesity, insulin resistance), hepatotoxicity, and renal toxicity, as well as pain-related disorders .
loading...
    loading...
Cat. No.: HY-W075903
CAS No.: 10534-89-1
Synonyms: Cobalt hexammine trichloride; Hexaamminecobalt trichloride
Hexaamminecobalt (III) chloride is an orally active cobalt coordination compound. Hexaamminecobalt (III) chloride restores the activities of liver antioxidant enzymes (SOD, Catalase) and detoxification enzyme GST. Hexaamminecobalt (III) chloride restores GSH content and reduces DAG. Hexaamminecobalt (III) chloride impairs renal function. Hexaamminecobalt (III) chloride exerts anti-carcinogenic effects in Diethylnitrosamine (HY-N7434)-induced hepatocarcinoma .
loading...
    loading...
Cat. No.: HY-W002942
CAS No.: 6640-50-2
Synonyms: 1,2,3,4-Tetrahydroquinolin-8-ol; 8-hydroxy-1,2,3,4-tetrahydroquinoline
Ferroptosis-IN-21 is a ferroptosis inhibitor that protects against renal I/R injury by suppressing ferroptosis and directly scavenging peroxyl radicals. Ferroptosis-IN-21 displays broad-spectrum anti-ferroptotic efficacy across multiple inducers in renal tubular epithelial cells, with nanomolar potency and robust suppression of lipid Reactive Oxygen Species (ROS). Ferroptosis-IN-21 significantly ameliorates renal I/R injury in mice, reducing histological damage, functional impairment, and inflammatory cytokine expression, while decreasing lipid peroxidation biomarkers such as 4-hydroxynonenal. Ferroptosis-IN-12 can be used for research in the field of ferroptosis-targeted drug development .
loading...
    loading...
Cat. No.: HY-110206
CAS No.: 1245626-05-4
Purity:  99.32%
Target:  

Cannabinoid Receptor

Research Areas:  

Metabolic Disease

AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist (Ki=1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications .
loading...
    loading...
Cat. No.: HY-175247
Research Areas:  

Cancer

DDO-4033 is a SPOP inhibitor (IC50 = 16.9 μM, Kd = 15.1 μM). DDO-4033 impairs the malignant migration, invasion, and proliferation of clear cell renal cell carcinoma (ccRCC) cell lines. DDO-4033 disrupts SPOP recruitment to its substrate LATS1, inhibits its polyubiquitination and subsequent degradation, and upregulates LATS1 expression. DDO-4033 has promising antitumor activity and is promising for renal cell carcinoma research .
loading...
    loading...
Cat. No.: HY-10965
CAS No.: 136199-02-5
Purity:  99.68%
Synonyms: KW-3902
Target:  

Adenosine Receptor

Research Areas:  

Neurological Disease

Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450) . Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-W416250
CAS No.: 17680-99-8
p-Cresol glucuronide is a metabolite of p-Cresol (HY-Y0506). p-Cresol glucuronide acts as a TLR4-antagonizing blood-brain barrier protective agent in brain microvascular endothelial cells, and serves as a non-invasive urinary biomarker metabolite in renal cell carcinoma. p-Cresol glucuronide inhibits LPS (HY-D1056)-induced increase in blood-brain barrier permeability and signal response, impairs mitochondrial function, induces oxidative stress and enhances inflammatory responses, depletes intracellular glutathione, and increases cell necrosis. p-Cresol glucuronide can be used in studies related to renal cell carcinoma, chronic kidney disease and heart disease .
loading...
    loading...
Cat. No.: HY-W766140
Synonyms: 4-Hydroxy duloxetine glucuronide sodium; LY550408 sodium
Target:  

Drug Metabolite

Research Areas:  

Metabolic Disease

4-Hydroxy duloxetine β-D-glucuronide (4-Hydroxy duloxetine glucuronide) sodium is a major metabolite of Duloxetine (HY-B0161). 4-Hydroxy duloxetine β-D-glucuronide sodium is promising for research of hepatic or renal impairment .
loading...
    loading...
Cat. No.: HY-117985
CAS No.: 1222102-29-5
Synonyms: DA-1229
Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
loading...
    loading...
Cat. No.: HY-14744D
CAS No.: 884648-62-8
Levamlodipine besylate Hemipentahydrate is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine besylate Hemipentahydrate significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine besylate Hemipentahydrate not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine besylate Hemipentahydrate exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine besylate Hemipentahydrate may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine besylate Hemipentahydrate can be used in research related to hypertension and atherosclerosis .
loading...
    loading...
Cat. No.: HY-117985A
CAS No.: 1246960-27-9
Synonyms: DA-1229 hydrochloride
Target:  

Dipeptidyl Peptidase

Research Areas:  

Metabolic Disease Endocrinology

Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
loading...
    loading...
Cat. No.: HY-117985S
Synonyms: DA-1229-d9
Evogliptin-d9 (DA-1229-d9) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
loading...
    loading...
Cat. No.: HY-10965R
CAS No.: 136199-02-5
Synonyms: KW-3902 (Standard)
Rolofylline (Standard) is the analytical standard of Rolofylline. This product is intended for research and analytical applications. Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450) . Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-14744B
CAS No.: 865430-76-8
Synonyms: (S)-Amlodipine hydrochloride; Levoamlodipine hydrochloride
Target:  

Calcium Channel MMP

Research Areas:  

Cardiovascular Disease

Levamlodipine ((S)-Amlodipine; Levoamlodipin) hydrochloride is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine hydrochloride significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine hydrochloride not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine hydrochloride exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine hydrochloride may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine hydrochloride can be used in research related to hypertension and atherosclerosis .
loading...
    loading...
Cat. No.: HY-14744S
CAS No.: 1346617-19-3
Purity:  99.74%
Synonyms: (S)-Amlodipine-d4; Levoamlodipine-d4
Levamlodipine-d4 is the deuterium labeled Levamlodipine. Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .
loading...
    loading...